Charge! Next-Generation LNP Assays with Waters Reversed Phase Charge Aerosol Detection
Lipid nanoparticle formulators often struggle to reproducibly separate components and resolve structurally similar analogues that can impact product safety and efficacy.
Currently, no single reversed-phase column or standardized separation method has been established, resulting in significant time and financial investment in method development.
In this webinar, we explore the properties and unique selectivity of our new lipid stationary phases, along with best practices and optimization strategies for LNP composition and critical impurity analysis critical for vaccines and emerging in vivo CAR-T. Learn how different detectors can enhance insight, how mobile phase additives can be used to tune selectivity, and how unique stationary phase properties enable robust, efficient method development from discovery through quality testing.
Why you should attend
- Understand how stationary phase properties affect LNP component separation.
- Learn how to tune selectivity by adjusting mobile phases for improved impurities quantitation.
- Identify optimal detection sources with UV, ELSD, CAD, and MS detection.
Who should attend
- Biopharma analytical development scientists
- Process development engineers
- QC and CMC scientists
- Lipid Synthesis chemists
- Lab managers and directors in biologics and advanced therapies
- Academic lab scientists including lipidomics
Speaker: Mateusz Imiolek, PhD (Principal Scientist, Waters Corporation)
Mateusz joined Waters in 2022 where he has been studying challenges associated with characterizing gene therapeutics and ensuring that new Waters products are fit for this purpose.
Before that, he completed his academic training in bioorganic chemistry, which allows him to apply detailed molecular insights to ensure the newly developed columns and assays are carefully designed for such analytes.
Speaker: Adam Kowalczyk (Research Scientist II – Analytical, Acuitas Therapeutics)
Adam is a Research Scientist II at Acuitas Therapeutics, where he specializes in analytical method development for lipid nanoparticle (LNP)‑based therapeutics. His work focuses on characterizing complex lipid systems, optimizing impurity profiling strategies, and supporting process development through robust analytical data.
With a strong background in chemistry and hands‑on experience in advanced LC and detection technologies, Adam brings deep technical insight into the challenges and requirements of modern LNP analysis.
